Keywords: Takeda, Alogliptin, Pioglitazone, Type 2 diabetes, USA, FDA, PUDFA date

US FDA sets PUDFA date for Takeda diabetes drug alogliptin and fixed-dose alogliptin/pioglitazone

Article | 02 November 2011

Print This

The US subsidiary of Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) said yesterday that the US Food and Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in